Fraser Eye Care Center | Fraser, MI
Status and phase
Conditions
Treatments
About
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Full description
This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with active TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as a series of subcutaneous/SC injections given every 4 weeks or every 8 weeks compared to placebo in participants with active TED.
Participants who do not have a meaningful response at Week 24 may be eligible to receive additional subcutaneous injections of VRDN-003.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
NOTE: There are additional eligibility criteria for non-responders who may receive additional injections of VRDN-003. These are described in the protocol.
Primary purpose
Allocation
Interventional model
Masking
84 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal